The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

NCT01676116 · Completed

Last updated 2026-05-28

This clinical trial tested a combination of insulin degludec and liraglutide in adults with type 2 diabetes whose blood sugar levels were not well controlled by GLP-1 receptor agonist and oral antidiabetic drugs.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 438 people

Who can join Ages 18+ · all sexes

Timeline Started 2012-08 · est. completion 2014-03

Where 109 sites · Australia, France, Hungary, Slovakia, United States

What this study is testing ClinicalTrials.gov NCT01676116 ↗

Description as written by the study sponsor.

This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.

Treatments tested

insulin degludec/liraglutide Drug

Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
liraglutide Drug

Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
exenatide Drug

Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.

Main thing measured	Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01676116 ↗